logo-loader
viewSynairgen PLC

Synairgen PLC's Richard Marsden hails positive results from study on COVID-19 patients

Synairgen PLC's (LON:SNG) chief executive Richard Marsden speaks to Proactive London's Andrew Scott soon after announcing positive results from the clinical trial of its drug to tackle the severe symptoms of coronavirus (COVID-19). He says the study could signal a major breakthrough in the treatment of hospitalised patients. The data revealed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe disease compared to those given the placebo.

Quick facts: Synairgen PLC

Price: 216 GBX

AIM:SNG
Market: AIM
Market Cap: £322.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: Wobbly FTSE 100 knocked by UK Chinese tensions despite...

Headlines from the Proactive UK newsroom. The FTSE 100 dropped 47 points to 6,243 even with good news on vaccines and treatments for COVID-19 from both sides of the Atlantic. Reports of big job cuts at M&S also dampened the mood. Synairgen (LON:SNG) shares almost trebled as it revealed...

2 weeks, 3 days ago

2 min read